- About us
- Clinical trials
- News & Publications
SOTIO® Biotech is developing the next generation of potent immunotherapies for patients with cancer.
The robust SOTIO Biotech pipeline includes both internally developed and in-licensed candidates for the treatment of a variety of solid tumor types.
SOTIO® Biotech is focused on advancing safer
and more effective immunotherapies
through clinical development.
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting new preclinical data at the Society for Immunotherapy of Cancer’s 38th Annual ...
SOTIO’s immunocytokine platform is designed to preferentially activate immune cells in the tumor microenvironment by targeted delivery of a cytokine agonist.
SOTIO’s BOXR cell therapy platform is designed to improve the functionality of engineered T cells by identifying novel “bolt-on” transgenes that can be co-expressed with tumor-targeting receptors to overcome resistance and improve the function of T cells in the solid tumor microenvironment.